Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...

A doctor has warned of the potential dangers of a 'game changing' diabetes drug which could rival the likes of Ozempic. The ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...

Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes (T2D) and Wegovy injections for weight management. Any price reduction ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...

The results make the tablet orforglipron ... agents is critical to future type 2 diabetes care.” Meanwhile, Novo Nordisk has finished trials for an oral semaglutide pill for obesity and has ...